ncoda.org
Aug 18, 2025, 18:55
NCODA Brings the BREAKWATER Trial into Practice
NCODA shared a post on LinkedIn:
“The BREAKWATER trial found that adding encorafenib + cetuximab to mFOLFOX6 improved survival versus standard first-line therapy in BRAF V600E–mutated metastatic colorectal cancer.
NCODA’s Positive Quality Intervention resource helps care teams put this regimen into practice safely, efficiently, and consistently, by providing:
- Clear dosing and infusion schedules for each drug in the regimen
- Pre-medication and antiemetic strategies to help patients avoid early toxicity
- Lab and ECG monitoring recommendations to catch issues before they escalate
- Supportive care approaches for rash, neuropathy, and GI side effects
- Access and assistance programs to reduce financial barriers
These practical, ready-to-use steps help ensure the benefits proven in the trial reach patients in everyday oncology care.
More posts featuring NCODA.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 18:55
Aug 18, 2025, 17:21
Aug 18, 2025, 17:13
Aug 18, 2025, 17:04
Aug 18, 2025, 16:37